SCHEMBL4371933

SCHEMBL4371933

C[C@H](OS(C)(=O)=O)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.32
GAA P10253 1/20 0.32
CYP2C9 P11712 1/20 0.32
PKM P14618 1/20 0.32
CYP2C19 P33261 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
KMT2A Q03164 1/20 0.32
USP2 O75604 1/20 0.32
TSHR P16473 1/20 0.32
PMP22 Q01453 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
SLC7A5 Q01650 1/20 0.31
CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3441094 1.00 ALDH1A1 (0.50) ALDH1A1TP53CYP1A2GAACYP2C9
SCHEMBL2781939 1.00 ALDH1A1 (0.50) ALDH1A1TP53CYP1A2GAACYP2C9
Propene SCHEMBL27907290 0.89 ALDH1A1 (0.41) ALDH1A1
SCHEMBL6451378 0.87 ALDH1A1 (0.39) ALDH1A1KMT2ACA14
SCHEMBL28223681 0.79 TP53 (0.36) ALDH1A1TP53CYP1A2GAACYP2C9
SCHEMBL31149010 0.79 TP53 (0.36) ALDH1A1TP53CYP1A2GAACYP2C9
SCHEMBL2329722 0.79 TP53 (0.36) ALDH1A1TP53CYP1A2GAACYP2C9
SCHEMBL14339239 0.79 ALDH1A1 (0.50) ALDH1A1USP2TSHRCA1CA2
SCHEMBL17210383 0.77 ALDH1A1 (0.48) ALDH1A1USP2TSHR
SCHEMBL16465564 0.77 ALDH1A1 (0.48) ALDH1A1USP2TSHRCA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060167292-A1 Process for preparing enantiomerically enriched 2-fluorocarboxylic esters LANXESS DEUTSCHLAND GMBH (DE) 2006-07-27 US claimed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 CN disclosed
CN-114127078-B Heterocompounds and methods of use thereof 重庆复创医药研究有限公司 2024-03-01 CN disclosed
CN-111511728-B Compound for separating rare earth elements and s, p, d metals, separation method and use thereof 有机生物化学公司 2023-12-08 CN disclosed
CN-114127078-A Hybrid compounds and methods of use thereof 重庆复创医药研究有限公司 2022-03-01 CN disclosed
EP-3717466-B1 COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2022-01-05 EP disclosed
CN-109575022-B Compound and application thereof 成都海博锐药业有限公司 2021-09-21 CN disclosed
EP-3717466-A1 COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2020-10-07 EP disclosed
US-20200282331-A1 COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2020-09-10 US disclosed
CN-111511728-A Compound for separating rare earth elements and s, p, d metals, separation method and use thereof 有机生物化学公司 2020-08-07 CN disclosed
EP-0759915-A1 ASYMMETRIC SYNTHESIS OF CHIRAL SECONDARY ALCOHOLS CELL THERAPEUTICS, INC. (US) 1997-03-05 EP disclosed
WO-1995031450-A1 ASYMMETRIC SYNTHESIS OF CHIRAL SECONDARY ALCOHOLS CELL THERAPEUTICS, INC. (US) 1995-11-23 WO disclosed
US-5210258-A Optically active alpha-naththylalkyl ketones SYNTEX PHARMACEUTICALS INTERNATIONAL LTD. (BM) 1993-05-11 US disclosed
EP-0230379-B1 CHROMAN- AND THIOCHROMAN-4-ACETIC ACIDS USEFUL IN THE TREATMENT OF DIABETIC COMPLICATIONS PFIZER INC. (US) 1991-04-03 EP disclosed
US-H774-H HERBICIDES NIHON NOHYAKU CO., LTD. (JP) 1990-05-01 US disclosed
US-4912254-A Preparation of α-arylalkanoic acids SYNTEX PHARMACEUTICAL INTERNATIONAL LIMITED (BM) 1990-03-27 US disclosed
EP-0081993-B1 OPTICALLY ACTIVE ALPHA-SUBSTITUTED ARYL KETONES, THEIR PREPARATION AND THEIR USE IN PREPARING ALPHA-ARYLALKANOIC ACIDS SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1988-08-17 EP disclosed
US-4749804-A Preparation of stereoisomers of ketals SYNTEX (U.S.A.) INC. (US) 1988-06-07 US disclosed
US-4605758-A Preparation of α-arylalkanoic acids SYNTEX PHARMACEUTICALS INTERNATIONAL LTD. (BM) 1986-08-12 US disclosed
EP-0081993-A2 Optically active alpha-substituted aryl ketones, their preparation and their use in preparing alpha-arylalkanoic acids SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1983-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167292-A1 Process for preparing enantiomerically enriched 2-fluorocarboxylic esters PHYKPL, PFAS, PFKFB2 ALDH1A1 1500/4885TP53 4638/4885CYP1A2 404/4885
US-20200282331-A1 COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF SCLY, SFXN1, PTCD3 ALDH1A1 2634/4885TP53 2392/4885CYP1A2 2784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.